Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Isolation of other micro‐organisms from the respiratory tract · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin FEV1: mean FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 285 participants | High |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin FVC: mean FVC % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 285 participants | High |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Growth and nutritional status: weight‐for‐age z score · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 285 participants | High |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | RR 0.78 [0.55, 1.1] | 1 study · 285 participants | High |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | RR 2.07 | 1 study · 285 participants | High |
Inhaled tobramycin (TNS) vs placebo Adverse effects of antibiotics: participants experiencing cough · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | OR 0.76 [0.1, 5.77] | 2 studies · 72 participants | Very low |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Adverse effects of antibiotics: · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | RR 0.97 | 1 study · 285 participants | Moderate |
Inhaled tobramycin (TNS) (28 days) vs TNS (56 days) Eradication of P aeruginosa from the respiratory tract: time to next isolation of P aeruginosa from BAL, sputum or oropharyngeal cultures · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) (28 days) vs TNS (56 days) FEV1: % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 88 participants | Very low |
Intervention NR Treatment time: time for a single nebulised treatment (min) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 3 studies · 88 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Serum deposition Cmax (µg/mL) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 5 studies · 126 participants | Low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | RR 0.78 [0.37, 1.64] | 2 studies · 60 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT FEV1:change in FEV1 % predicted · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 49 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Treatment time nebulisation time (min) · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Quality of life · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Serum deposition Cmax (µg/mL) · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Adverse events · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD FEV1 Change in FEV1 % predicted · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Intervention NR Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Time to next exacerbation · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Participant satisfaction or preference Satisfaction scale · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | MD 2.7 [1.35, 4.05] | 1 study · 22 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Treatment time (min) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Serum deposition: Cmax (mg/L) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD FEV1 · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Treatment time (min) · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Intervention NR Serum deposition: Cmax (µg/mL) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 10 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Serum deposition Cmax · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 18 participants | Very low |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Time to next exacerbation · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Participant satisfaction or preference · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Treatment time (seconds) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 15 participants | Very low |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Serum deposition (Cmax) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events: bronchoconstriction · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 20 studies · 78 participants | Very low |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD FEV1 change from baseline · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 15 participants | Very low |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 259 participants | Very low |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | RR 0.45 [0.35, 0.57] | 1 study · 259 participants | Low |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Treatment time (minutes) · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |